BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Blidisel A, Marcovici I, Coricovac D, Hut F, Dehelean CA, Cretu OM. Experimental Models of Hepatocellular Carcinoma-A Preclinical Perspective. Cancers (Basel) 2021;13:3651. [PMID: 34359553 DOI: 10.3390/cancers13153651] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Chen L, Wei X, Gu D, Xu Y, Zhou H. Human liver cancer organoids: Biological applications, current challenges, and prospects in hepatoma therapy. Cancer Lett 2023;555:216048. [PMID: 36603689 DOI: 10.1016/j.canlet.2022.216048] [Reference Citation Analysis]
2 Zuchowska A, Skorupska S. Multi-organ-on-chip approach in cancer research. Organs-on-a-Chip 2022;4:100014. [DOI: 10.1016/j.ooc.2021.100014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
3 Zhang J, Han H, Wang L, Wang W, Yang M, Qin Y. Overcoming the therapeutic resistance of hepatomas by targeting the tumor microenvironment. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.988956] [Reference Citation Analysis]
4 Dehelean CA, Coricovac D, Pinzaru I, Marcovici I, Macasoi IG, Semenescu A, Lazar G, Cinta Pinzaru S, Radulov I, Alexa E, Cretu O. Rutin bioconjugates as potential nutraceutical prodrugs: An in vitro and in ovo toxicological screening. Front Pharmacol 2022;13:1000608. [DOI: 10.3389/fphar.2022.1000608] [Reference Citation Analysis]
5 Owis AI, Sherif NH, Hassan AA, El-Naggar EB, El-Khashab IH, El-Ghaly ES. Tropaeolum majus L. and low dose gamma radiation suppress liver carcinoma development via EGFR-HER2 signaling pathway. Nat Prod Res 2022;:1-6. [PMID: 35834717 DOI: 10.1080/14786419.2022.2098958] [Reference Citation Analysis]
6 Tulessin M, Sarker RSJ, Griger J, Leibing T, Geraud C, Weichert W, Steiger K, Mogler C. Vascular Remodeling Is a Crucial Event in the Early Phase of Hepatocarcinogenesis in Rodent Models for Liver Tumorigenesis. Cells 2022;11:2129. [DOI: 10.3390/cells11142129] [Reference Citation Analysis]
7 Rednic R, Marcovici I, Dragoi R, Pinzaru I, Dehelean CA, Tomescu M, Arnautu DA, Craina M, Gluhovschi A, Valcovici M, Manea A. In Vitro Toxicological Profile of Labetalol-Folic Acid/Folate Co-Administration in H9c2(2-1) and HepaRG Cells. Medicina (Kaunas) 2022;58:784. [PMID: 35744047 DOI: 10.3390/medicina58060784] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Gu CY, Lee TKW. Preclinical mouse models of hepatocellular carcinoma: An overview and update. Experimental Cell Research 2022. [DOI: 10.1016/j.yexcr.2022.113042] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Yu JH, Ma S. Organoids as research models for hepatocellular carcinoma. Exp Cell Res 2021;411:112987. [PMID: 34942189 DOI: 10.1016/j.yexcr.2021.112987] [Reference Citation Analysis]
10 Ghufran H, Azam M, Mehmood A, Butt H, Riazuddin S. Standardization of diethylnitrosamine-induced hepatocellular carcinoma rat model with time based molecular assessment. Exp Mol Pathol 2021;123:104715. [PMID: 34699901 DOI: 10.1016/j.yexmp.2021.104715] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]